Hormone-Refractory Prostate Cancer

Hormone-refractory prostate cancer represents an advanced stage where cancer continues to grow despite treatments that lower testosterone levels, presenting both complex challenges and evolving treatment options for patients and their healthcare teams.

Table of contents

• What is hormone-refractory prostate cancer?
• Understanding the different terms
• How doctors diagnose this condition
• Common health problems patients experience
• Treatment options available
• How doctors measure if treatment is working
• What to expect: survival and prognosis

What is hormone-refractory prostate cancer?

Hormone-refractory prostate cancer is a form of prostate cancer that keeps growing even when doctors have lowered the body’s testosterone (the main male hormone) to very low levels. This happens after initial hormone treatments that were working at first stop being effective^[1].

As prostate cancer advances, it shows different levels of sensitivity to hormones. At first, cancer cells are similar to normal prostate tissue and shrink when male hormones are removed. However, some cancers eventually learn to grow despite having very little testosterone in the body^[1].

The condition is defined as cancer growth that happens even when testosterone levels in the blood are at or below what doctors call “castrate levels” – typically less than 50 nanograms per deciliter. This low testosterone level is usually achieved either through medications called LHRH agonists (drugs that reduce hormone production) or through surgical removal of the testicles^[3].

castration-resistant prostate cancer, hormone-resistant prostate cancer, androgen-independent prostate cancer

Understanding the different terms

You may hear several different names used to describe this condition, and understanding what they mean can help reduce confusion. The terms “hormone-refractory prostate cancer,” “castration-resistant prostate cancer,” and “hormone-resistant prostate cancer” all refer to the same basic problem – cancer that continues to grow despite very low testosterone levels^[4].

In the past, doctors also used terms like “androgen-independent” or “hormone refractory,” but these are less common today. The newer term “castration-resistant” is more accurate because the cancer isn’t truly independent of hormones for its growth. In fact, some newer hormone therapies can still be effective even at this stage^[2].

Before a doctor labels prostate cancer as truly hormone-refractory, they should ideally try all available hormone-based treatments, including at least what’s called androgen withdrawal (stopping certain hormone-blocking medications)^[6].

There are two main types of this condition. Non-metastatic castration-resistant prostate cancer means the cancer hasn’t spread to other parts of the body based on scans. Metastatic castration-resistant prostate cancer means the cancer has spread to lymph nodes or other areas like the bones^[4].

How doctors diagnose this condition

Your doctor will know you have hormone-refractory prostate cancer based on several pieces of information. The most important sign is when a blood test shows your PSA (prostate-specific antigen) level is rising, even though your testosterone level remains low. Usually, doctors look for at least two increases in PSA levels, taken at least one week apart using the same testing method^[3].

Imaging tests may also show that the cancer has started to grow again. These tests can include bone scans and CT scans, which help doctors see whether cancer has spread to other parts of the body^[4].

It’s important to confirm that testosterone levels are truly at castrate levels – below 50 nanograms per deciliter. In some studies, surgical removal of the testicles failed to produce castrate testosterone levels in about 11% of cases. If testosterone isn’t low enough, that could explain why the cancer is still growing^[1].

Doctors may also look at something called PSA doubling time, which is how long it takes for the PSA level to double. This information helps them decide on the best treatment approach^[4].

Common health problems patients experience

Patients with hormone-refractory prostate cancer can face various symptoms and complications as the disease progresses. Understanding these problems helps patients and their families prepare and seek appropriate support.

Many patients experience problems with urination. This can include difficulty passing urine, blood in the urine, or complete blockage of the urinary channel. The cancer can also block the tubes (called ureters) that carry urine from the kidneys to the bladder^[6].

Bone problems are very common because prostate cancer often spreads to bones, particularly the spine, hips, and pelvis. This can cause significant pain and in some cases lead to fractures without warning. When cancer affects the bone marrow (the part of bones that makes blood cells), it can cause serious anemia and weakness^[6].

Other complications can include swelling in the legs (lymphedema), problems with the rectum, pelvic pain, and neurological problems if cancer affects the nerves. Many patients also experience psychological difficulties and a reduced quality of life as they cope with these various challenges^[6].

Treatment options available

Even though hormone-refractory prostate cancer is challenging to treat, several options exist. Treatment choices depend on many factors, including whether the cancer has spread, the patient’s symptoms, age, other health conditions, and how fast the PSA is rising^[3].

Additional hormone treatments

Even when initial hormone therapy stops working, other hormone-based treatments may still help. These are called secondary hormonal maneuvers. Many patients respond to these additional treatments before needing chemotherapy^[1].

For patients with non-metastatic disease (cancer that hasn’t spread), doctors usually continue some type of hormone therapy. They may add medications like anti-androgens – drugs such as apalutamide, enzalutamide, or darolutamide. Interestingly, if you’re already taking an anti-androgen, sometimes stopping it can actually slow cancer growth for a while^[4].

For patients with metastatic disease (cancer that has spread), doctors may add different hormone therapies, including anti-androgens or androgen synthesis inhibitors like abiraterone. These drugs work by blocking the production of male hormones throughout the entire body, including by the cancer cells themselves^[4].

Chemotherapy

Chemotherapy uses anti-cancer drugs to destroy cancer cells. It’s particularly useful for metastatic castration-resistant prostate cancer that is causing symptoms. Only chemotherapy with docetaxel (a drug also known as Taxotere) has been proven to improve survival in this setting. Docetaxel is usually given every three weeks^[3][4].

Chemotherapy often works better when combined with ongoing hormone therapy. The combination can control metastatic prostate cancer for many months, though eventually the cancer usually starts growing again^[4].

Palliative treatments

Because the primary role of treatment at this stage is to improve quality of life and manage symptoms, several approaches focus on comfort and symptom relief. These palliative treatments are critical for appropriate patient care^[3].

External-beam radiation can target specific areas causing problems. Bisphosphonate therapy helps strengthen bones and reduce bone-related complications. Radiopharmaceuticals (radioactive substances given through the vein) can help reduce bone pain when cancer has spread to multiple bones. Good pain management is essential for maintaining quality of life^[3].

Experimental options and clinical trials

Several promising new therapies are being tested in late-stage clinical trials. Participating in a clinical trial might give you access to cutting-edge treatments that aren’t yet widely available^[3].

How doctors measure if treatment is working

Determining whether treatment is helping can be complex because most patients with hormone-refractory prostate cancer don’t have tumors that can be easily measured. Bone metastases, which are common, are particularly difficult to measure accurately^[1].

Today, doctors primarily use PSA levels to track response to treatment. Many studies have shown a connection between how much PSA decreases after therapy and how long patients survive. Research at Memorial Sloan-Kettering Cancer Center found that patients whose PSA dropped by 50% or more after treatment had significantly better survival – a median of 21 months compared to just 8 months for those with less than 50% decline^[1].

However, PSA levels alone don’t tell the whole story. Because treatment at this stage focuses on improving quality of life and managing symptoms, doctors also pay close attention to whether symptoms improve. Many patients experience significant bone pain and reduced quality of life, so relief from these problems is an important measure of whether treatment is working^[1].

The recommended approach is to look at PSA data, symptom relief, and changes in measurable disease separately, giving a complete picture of how treatment is affecting the patient^[1].

What to expect: survival and prognosis

The outlook for hormone-refractory prostate cancer varies significantly from person to person. Historically, patients with this condition were expected to survive about 12 to 18 months after the cancer became hormone-resistant^[6].

However, more recent studies show improved survival times. In one study, the median survival after developing hormone-refractory disease was approximately 40 months for patients with skeletal metastases and 68 months for those without skeletal metastases. This improvement reflects better detection through PSA testing and advances in treatment^[6].

The disease follows a prolonged course. Research shows that even after PSA levels begin rising after surgery, the median time until death can be 13 years. This extended timeline means that many patients live for years even after their cancer becomes hormone-refractory^[3].

While hormone-refractory prostate cancer is currently incurable, ongoing research continues to develop new treatments that may extend survival and improve quality of life. The key is working closely with your healthcare team to find the treatment approach that best fits your individual situation^[3].